ライフサイエンスコーパス: sprint

1 Systolic Blood Pressure Intervention Trial (SPRINT).

2 This performs well with SPRINT.

3 c mortality, calibrated to rates reported in SPRINT.

4 .S. adults meet the eligibility criteria for SPRINT.

5 ost of whom would not have been eligible for SPRINT.

6 cted benefit and more predicted risk than in SPRINT.

7 9): one session of 4 x 30 s cycle ergometer sprints.

8 ing rules (detectable HCV RNA at week 24 for SPRINT-2 and at week 12 for RESPOND-2) could be refined

9 In the SPRINT-2 trial, factors that predicted a SVR to triple t

10 rom the Serine Protease Inhibitor Therapy 2 (SPRINT-2) study (treatment-naive patients) and the Retre

11 In SPRINT-2, a week 12 rule with an HCV RNA cutoff of >/= 1

12 rom the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior

13 mm Hg), only a few would have qualified for SPRINT (27.0% and 21.9% of untreated and treated patient

14 portion of whom would have been eligible for SPRINT (5.4% untreated, 13.9% treated) or HOPE-3 (13.9%

15 Of U.S. adults eligible for SPRINT, 51.0% (95% CI: 47.8% to 54.1%) or 8.6 million (9

16 eds might originate from intrinsically lower sprinting abilities of athletes with BKA or from more co

17 Systolic Blood Pressure Intervention Trial (SPRINT), adults at high risk for cardiovascular disease

18 t among the 6 key, prespecified subgroups in SPRINT: age >/=75 years, prior cardiovascular disease, c

19 SPRINT allows the biostatistician to concentrate on the

20 p identify subgroups of participants in both SPRINT and ACCORD-BP who had lower versus higher ARRs in

21 eed to occur at 3 times the rate observed in SPRINT and be 3 times more common in the intensive manag

22 s with SBP of 120 mm Hg or higher, including SPRINT and HOPE-3 eligibility, and estimated who may hav

23 ectives: To assess the representativeness of SPRINT and HOPE-3 relative to patients in the United Sta

24 alpha-actinin-3 deficiency is detrimental to sprint and power performance in both elite athletes and

25 cultures: Texel DCM-1, Texel LM-30, Biostar Sprint, and SM-181.

26 Humans sprinting around banked bends change the duration of foo

27 The 2004 Olympic women's 100-metre sprint champion, Yuliya Nesterenko, is assured of fame a

28 and determine the broader population to whom SPRINT could be generalized.

29 Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the benefit of lowering systolic bl

30 , and characteristics of U.S. adults meeting SPRINT eligibility criteria and determine the broader po

31 treated hypertension, the percentage meeting SPRINT eligibility criteria increased with older age, wa

32 SPRINT eligibility criteria were applied to the 1999 to

33 on) adults with treated hypertension met the SPRINT eligibility criteria.

34 SPRINT eligibility included age >/=50 years, SBP of 130

35 national sources to a hypothetical cohort of SPRINT-eligible adults.

36 Sprint Fidelis (Fidelis) implantable cardioverter-defibr

37 safety and feasibility of extraction of the Sprint Fidelis (Medtronic, Minneapolis, Minnesota) lead.

38 onsecutive patients undergoing extraction of Sprint Fidelis (models 6930, 6931, 6948, 6949) leads at

39 Sprint Fidelis (SF) (Medtronic, Inc., Minneapolis, Minne

40 urvival analyses on our 3-center database of Sprint Fidelis and Quattro Secure implantable cardiovert

41 cardioverter-defibrillator leads such as the Sprint Fidelis are limited.

42 The reported failure rate of the Sprint Fidelis defibrillator lead has increased to a ran

43 The Sprint Fidelis implantable cardioverter-defibrillator le

44 Extraction of the Sprint Fidelis lead can be performed safely by experienc

45 Recommendations regarding prophylactic Sprint Fidelis lead extraction may warrant reconsiderati

46 Sprint Fidelis leads are prone to pace-sense lead fractu

47 Between May 2005 and August 2009, 349 Sprint Fidelis leads were extracted from 348 patients.

48 A total of 3169 Sprint Fidelis leads were implanted in 11 centers with a

49 no differences in the quantity or length of sprints (>24 km h(-1)) between CON and HOT.

50 The SPRINT inclusion criteria were age >/=50 years, SBP 130

51 quantify the potential benefits and risks of SPRINT intensive goal implementation, we estimated the d

52 xcess serious adverse events incurred if the SPRINT intensive SBP treatment goal were implemented in

53 ntly, in the Systolic BP Intervention Trial (SPRINT), intensive lowering of clinic systolic BP to a t

54 nged in a coordinate manner in response to a sprint interval exercise training regimen in humans and

55 Second, we hypothesized that sprint interval training (SIT) also promotes increases i

56 Sprint interval training (SIT) and traditional endurance

57 e exercise performance in adult humans after sprint interval training (SIT) has been attributed to mi

58 Sprint interval training (SIT) has been proposed as a ti

59 Sprint interval training (SIT) has been proposed as a ti

60 Sprint interval training (SIT) has been proposed as a ti

61 In human subjects, sprint interval training primarily stimulated synthesis

62 The Simple Parallel R INTerface (SPRINT) is a wrapper around such parallelised functions.

63 d, where addition of starter culture Biostar Sprint (Lactobacillus sakei, Staphylococcus carnosus, St

64 ne in the control group were able to achieve SPRINT levels without antihypertensives.

65 s with BKA or from more complex adaptions in sprinting mechanics due to the biomechanical and morphol

66 of a heart attack and the leg pain of a 30 s sprint--occurs when muscle gets too little oxygen for it

67 e step from a transition state by a unitary "sprint" of approximately 7.8 nm.

68 t during recovery from an exhaustive 1-2 min sprint on a bicycle ergometer with a workload of 400 W.

69 When executed using SPRINT on an HPC resource of eight processors this compu

70 ed how the Namib Day Gecko, Rhoptropus afer, sprints on ecologically relevant substrates.

71 SPRINT participants in the highest predicted benefit sub

72 Similarly, among SPRINT participants with baseline LVH (n=605, 7.4%), tho

73 Data from 9,069 SPRINT participants with complete data on covariates wer

74 Among SPRINT participants without baseline LVH (n=7559), inten

75 Among 9361 SPRINT patients, 755 patients (8.1%) had a MACE or death

76 ation, body weight loss as well as post-game sprint performance were similar between the two conditio

77 tensive (versus standard) BP lowering on the SPRINT primary CVD outcome (a composite of myocardial in

78 Systolic Blood Pressure Intervention Trial (SPRINT) provide background information and context on th

79 red horse population that are best suited to sprint racing.

80 ors have questioned the ability to translate SPRINT results into routine clinical practice, in which

81 on with the release of detailed results from SPRINT's primary analysis.

82 lder receiving treatment for hypertension, a SPRINT SBP level of 120 mm Hg or lower was not associate

83 Fast sprint speed evolved several times in lizards, including

84 the subdigital adhesive toe pad may increase sprint speed in this species.

85 1)) by 26% in HOT compared to CON), but peak sprint speed was 4% higher (P<0.05) in HOT than in CON,

86 However, peak sprinting speed and execution of successful passes and c

87 We found slower maximum sprinting speeds in athletes with BKA, but did not find

88 s ran at self-selected endurance running and sprinting speeds.

89 The MCL-002 (SPRINT) study was a randomised, phase 2 study of patient

90 Systolic Blood Pressure Intervention Trial (SPRINT) suggested that a SBP level of lower than 120 mm

91 Sprinting, swimming, and jumping performance of ectother

92 SPRINT (Systolic Blood Pressure Intervention Trial) demo

93 g one, and 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) elig

94 re (SBP) treatment goal is in question, with SPRINT (Systolic Blood Pressure Intervention Trial) sugg

95 is for the primary end point considering the SPRINT (Systolic Blood Pressure Intervention Trial) targ

96 SPRINT (Systolic Blood Pressure Intervention Trial) was

97 In SPRINT (Systolic Blood Pressure Intervention Trial), a s

98 In SPRINT (Systolic Blood Pressure Intervention Trial), pat

99 Subgroup analyses of SPRINT (Systolic Blood Pressure Intervention Trial).

100 lure (ADHF) was a frequent common outcome in SPRINT (Systolic Blood Pressure Intervention Trial).

101 lite players during the games and a repeated sprint test was conducted after the two game trials.

102 regulator of dynein-dependent transport) and Sprint (the guanine nucleotide exchange factor for Rab5)

103 To translate the findings from SPRINT to clinical practice, we developed prediction mod

104 Systolic Blood Pressure Intervention Trial (SPRINT) to estimate treatment effects and adverse event

105 We used a microsimulation model to apply SPRINT treatment effects and health care costs from nati

106 pertension but no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial

107 METHODS AND Cox models were derived from SPRINT trial data and validated on ACCORD-BP trial data

108 and explore how ambulatory BP data from the SPRINT trial may inform this discussion.

109 associated with intensive BP lowering in the SPRINT trial.

110 ed on a level surface while contributions to sprinting uphill are more evenly distributed among motio

111 -level data from 9361 randomized patients in SPRINT, we developed models to predict risk for MACE or

112 absolute risks for serious adverse events in SPRINT were used to estimate the number of potential dea

113 nsive therapy in mild to moderate CKD, where SPRINT will help to inform practice, as well as where ga